FLGT · Fulgent Genetics, Inc. · Investor Relations

EL MONTE, Calif. --(BUSINESS WIRE)--Oct. 15, 2026-- Fulgent Genetics, Inc. (NASDAQ: FLGT) (“Fulgent” or the “Company”), a technology-based company with a well-established laboratory services business and a therapeutic development business, today announced that it will release its third quarter 2026

Revenue of $85.4 million, growing 20.1% sequentially GAAP gross profit of $25.7 million, or GAAP gross margin of 30.1%; Non-GAAP gross profit of $26.8 million, or Non-GAAP gross margin of 31.3% GAAP loss of $29.5 million, or $(1.05) per share; Non-GAAP loss of $16.2 million, or $(0.58) per share

EL MONTE, Calif. --(BUSINESS WIRE)--Jul. 9, 2026-- Fulgent Genetics, Inc. (NASDAQ: FLGT) (“Fulgent” or the “Company”), a technology-based company with a well-established laboratory services business and a therapeutic development business, today announced that it will release its second quarter 2026

EL MONTE, Calif. --(BUSINESS WIRE)--Jun. 1, 2026-- Fulgent Genetics, Inc. (NASDAQ: FLGT) (“Fulgent” or the “Company”), a technology-based company with established laboratory services and therapeutic development businesses, today announced it presented updated data in the Head and Neck Cancer Track

EL MONTE, Calif. --(BUSINESS WIRE)--May 21, 2026-- Fulgent Genetics, Inc. (NASDAQ: FLGT) (“Fulgent” or the “Company”), a technology-based company with a well-established laboratory services business and a therapeutic development business, today announced that its full abstract has been released on

Reiterates revenue guidance for fiscal year 2026 Executed on stock repurchase program; purchased approximately 2.6 million shares in the first quarter of 2026 using $40.1 million in cash Revenue of $71.1 million GAAP gross profit of $21.5 million, or GAAP gross margin of 30.2%; Non-GAAP gross

EL MONTE, Calif. --(BUSINESS WIRE)--Apr. 22, 2026-- Fulgent Genetics, Inc. (NASDAQ: FLGT) (“Fulgent” or the “Company”), a technology-based company with a well-established laboratory services business and a therapeutic development business, today announced that its abstract was selected to be

EL MONTE, Calif. --(BUSINESS WIRE)--Apr. 16, 2026-- Fulgent Genetics, Inc. (NASDAQ: FLGT) (“Fulgent” or the “Company”), a technology-based company with a well-established laboratory services business and a therapeutic development business, today announced that it will release its first quarter 2026

EL MONTE, Calif. --(BUSINESS WIRE)--Mar. 17, 2026-- Fulgent Genetics, Inc. (NASDAQ: FLGT) (“Fulgent”), a technology-based company with a well-established laboratory services business and a therapeutic development business, today announced the completion of the acquisition of Bako Diagnostics, a

Revenue of $83.3 million, growing 9% year-over-year GAAP gross profit of $32.6 million, or GAAP gross margin of 39.1%; Non-GAAP gross profit of $34.2 million, or Non-GAAP gross margin of 41.0% GAAP loss of $23.4 million, or ( $0.76) per share; Non-GAAP income of $5.2 million, or $0.16 per share

EL MONTE, Calif. --(BUSINESS WIRE)--Feb. 12, 2026-- Fulgent Genetics, Inc. (NASDAQ: FLGT) (“Fulgent” or the “Company”), a technology-based company with a well-established laboratory services business and a therapeutic development business, today announced that it will release its fourth quarter and

Proposed acquisition will add new anatomic pathology services, proprietary PCR tests and a national client base EL MONTE, Calif. --(BUSINESS WIRE)--Dec. 22, 2025-- Fulgent Genetics, Inc. (NASDAQ: FLGT) (“Fulgent”), a technology-based company with a well-established laboratory services business and

EL MONTE, Calif. --(BUSINESS WIRE)--Nov. 7, 2025-- Fulgent Genetics, Inc. (NASDAQ: FLGT) (“Fulgent,” or the “Company”), a technology-based company with a well-established laboratory services business and a therapeutic development business, today announced that members of its management team are